CBT-101 (CHA Biotech)

N/A

Report date: 2025/04/15 11:46:05

Base Information

Drug NameCBT-101 (CHA Biotech)
Drug Alias NameAutologous Natural Killer Cell therapyCHANK-101CBT-101
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCHA Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKorea Drug Develpment FundCHA Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A